Registration effective
Open the filing on sec.gov
Werewolf Therapeutics, Inc. (HOWL)
Nasdaq: HOWL · Pharmaceutical Preparations · Watertown, MA · filing with the SEC since 2019
The companyfiscal 2025, as filed
Revenuen/a
Net income-$60.8M+13.7%
Earnings per share$-1.33+18.4%
Operating cash flow-$60.3M-7.3%
Cash$58.0M-48.4%
Debt$32.1M0.0%
Shareholders’ equity$24.8M-66.2%
Shares, diluted46.8M+6.7%
Return on equity-245.2%
The recordfrom its filings
Filings in 2026106
Newest filingNov 12 · EFFECT
Annual reportMar 27, 2026
Quarterly reportJul 31, 2026
Next report due10-Q by Nov 14
Insider sales, 12 months$4.2M
Insider buys, 12 months$0.00
Patents granted10
Filer categoryNon-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Trailing twelve months to Jun 2026Net income -$34.6MCash from operations -$30.1Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Shelf offering
Open the filing on sec.gov
Merger or exchange registration, amended
Open the filing on sec.gov
Merger communication
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Merger or exchange registration, amended
Open the filing on sec.gov
Merger or exchange registration
Open the filing on sec.gov
Large holder notice
Open the filing on sec.gov
Merger communication
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.